Safety, tolerability, and efficacy of everolimus in De Novo liver transplant recipients

12- and 36-month results

Gary Levy, Heinz Schmidli, Jeffrey Punch, Elizabeth Tuttle-Newhall, David Mayer, Peter Neuhaus, Didier Samuel, Bjorn Nashan, Juergen Klempnauer, Alan Norman Langnas, Yvon Calmus, Xavier Rogiers, Michael Abecassis, Richard Freeman, Maarten Sloof, John Roberts, Lutz Fischer

Research output: Contribution to journalArticle

101 Citations (Scopus)

Abstract

Everolimus is a macrolide immunosuppressive agent with known consistent absorption. In this double-blind study, we examined the safety and tolerability of everolimus vs. placebo in de novo liver transplant recipients. One hundred and nineteen liver allograft recipients were randomized to 1 of 4 groups: everolimus 0.5 mg bid, everolimus 1.0 mg bid, everolimus 2 mg bid, or placebo. Patients received oral cyclosporine to achieve a target trough level of 150-400 ng/mL in combination with prednisone. Primary and secondary endpoints of safety, tolerability, and efficacy were determined at 12 months, and patients were followed through 36 months. There was a trend toward fewer treated acute rejections in the everolimus group than in the placebo group: everolimus 0.5 mg: 39.3%; everolimus 1.0 mg: 30.0%; everolimus 2 mg: 29.0%; placebo: 40.0% (P = not significant). Adverse events were higher in everolimus-treated patients especially at the 4-mg/day dose, but there was no difference in the incidence of thrombocytopenia or leukopenia between all groups and renal function as determined by serum creatinine, and creatinine clearance remained stable to 36 months in everolimus-treated patients. Mean cholesterol and triglycerides increased from baseline in all treatment groups, and maximum levels were seen at 6 months. In conclusion, this study demonstrates that everolimus in combination with oral cyclosporine had an acceptable safety and tolerability profile, paving the way for additional studies in this transplant indication.

Original languageEnglish (US)
Pages (from-to)1640-1648
Number of pages9
JournalLiver Transplantation
Volume12
Issue number11
DOIs
StatePublished - Nov 1 2006

Fingerprint

Safety
Liver
Placebos
Cyclosporine
Everolimus
Transplant Recipients
Creatinine
Macrolides
Leukopenia
Immunosuppressive Agents
Prednisone
Double-Blind Method
Thrombocytopenia
Allografts
Triglycerides
Cholesterol
Transplants
Kidney
Incidence
Serum

ASJC Scopus subject areas

  • Surgery
  • Hepatology
  • Transplantation

Cite this

Levy, G., Schmidli, H., Punch, J., Tuttle-Newhall, E., Mayer, D., Neuhaus, P., ... Fischer, L. (2006). Safety, tolerability, and efficacy of everolimus in De Novo liver transplant recipients: 12- and 36-month results. Liver Transplantation, 12(11), 1640-1648. https://doi.org/10.1002/lt.20707

Safety, tolerability, and efficacy of everolimus in De Novo liver transplant recipients : 12- and 36-month results. / Levy, Gary; Schmidli, Heinz; Punch, Jeffrey; Tuttle-Newhall, Elizabeth; Mayer, David; Neuhaus, Peter; Samuel, Didier; Nashan, Bjorn; Klempnauer, Juergen; Langnas, Alan Norman; Calmus, Yvon; Rogiers, Xavier; Abecassis, Michael; Freeman, Richard; Sloof, Maarten; Roberts, John; Fischer, Lutz.

In: Liver Transplantation, Vol. 12, No. 11, 01.11.2006, p. 1640-1648.

Research output: Contribution to journalArticle

Levy, G, Schmidli, H, Punch, J, Tuttle-Newhall, E, Mayer, D, Neuhaus, P, Samuel, D, Nashan, B, Klempnauer, J, Langnas, AN, Calmus, Y, Rogiers, X, Abecassis, M, Freeman, R, Sloof, M, Roberts, J & Fischer, L 2006, 'Safety, tolerability, and efficacy of everolimus in De Novo liver transplant recipients: 12- and 36-month results', Liver Transplantation, vol. 12, no. 11, pp. 1640-1648. https://doi.org/10.1002/lt.20707
Levy, Gary ; Schmidli, Heinz ; Punch, Jeffrey ; Tuttle-Newhall, Elizabeth ; Mayer, David ; Neuhaus, Peter ; Samuel, Didier ; Nashan, Bjorn ; Klempnauer, Juergen ; Langnas, Alan Norman ; Calmus, Yvon ; Rogiers, Xavier ; Abecassis, Michael ; Freeman, Richard ; Sloof, Maarten ; Roberts, John ; Fischer, Lutz. / Safety, tolerability, and efficacy of everolimus in De Novo liver transplant recipients : 12- and 36-month results. In: Liver Transplantation. 2006 ; Vol. 12, No. 11. pp. 1640-1648.
@article{5379a5e9537647caaa3326853bf44d0a,
title = "Safety, tolerability, and efficacy of everolimus in De Novo liver transplant recipients: 12- and 36-month results",
abstract = "Everolimus is a macrolide immunosuppressive agent with known consistent absorption. In this double-blind study, we examined the safety and tolerability of everolimus vs. placebo in de novo liver transplant recipients. One hundred and nineteen liver allograft recipients were randomized to 1 of 4 groups: everolimus 0.5 mg bid, everolimus 1.0 mg bid, everolimus 2 mg bid, or placebo. Patients received oral cyclosporine to achieve a target trough level of 150-400 ng/mL in combination with prednisone. Primary and secondary endpoints of safety, tolerability, and efficacy were determined at 12 months, and patients were followed through 36 months. There was a trend toward fewer treated acute rejections in the everolimus group than in the placebo group: everolimus 0.5 mg: 39.3{\%}; everolimus 1.0 mg: 30.0{\%}; everolimus 2 mg: 29.0{\%}; placebo: 40.0{\%} (P = not significant). Adverse events were higher in everolimus-treated patients especially at the 4-mg/day dose, but there was no difference in the incidence of thrombocytopenia or leukopenia between all groups and renal function as determined by serum creatinine, and creatinine clearance remained stable to 36 months in everolimus-treated patients. Mean cholesterol and triglycerides increased from baseline in all treatment groups, and maximum levels were seen at 6 months. In conclusion, this study demonstrates that everolimus in combination with oral cyclosporine had an acceptable safety and tolerability profile, paving the way for additional studies in this transplant indication.",
author = "Gary Levy and Heinz Schmidli and Jeffrey Punch and Elizabeth Tuttle-Newhall and David Mayer and Peter Neuhaus and Didier Samuel and Bjorn Nashan and Juergen Klempnauer and Langnas, {Alan Norman} and Yvon Calmus and Xavier Rogiers and Michael Abecassis and Richard Freeman and Maarten Sloof and John Roberts and Lutz Fischer",
year = "2006",
month = "11",
day = "1",
doi = "10.1002/lt.20707",
language = "English (US)",
volume = "12",
pages = "1640--1648",
journal = "Liver Transplantation",
issn = "1527-6465",
publisher = "John Wiley and Sons Ltd",
number = "11",

}

TY - JOUR

T1 - Safety, tolerability, and efficacy of everolimus in De Novo liver transplant recipients

T2 - 12- and 36-month results

AU - Levy, Gary

AU - Schmidli, Heinz

AU - Punch, Jeffrey

AU - Tuttle-Newhall, Elizabeth

AU - Mayer, David

AU - Neuhaus, Peter

AU - Samuel, Didier

AU - Nashan, Bjorn

AU - Klempnauer, Juergen

AU - Langnas, Alan Norman

AU - Calmus, Yvon

AU - Rogiers, Xavier

AU - Abecassis, Michael

AU - Freeman, Richard

AU - Sloof, Maarten

AU - Roberts, John

AU - Fischer, Lutz

PY - 2006/11/1

Y1 - 2006/11/1

N2 - Everolimus is a macrolide immunosuppressive agent with known consistent absorption. In this double-blind study, we examined the safety and tolerability of everolimus vs. placebo in de novo liver transplant recipients. One hundred and nineteen liver allograft recipients were randomized to 1 of 4 groups: everolimus 0.5 mg bid, everolimus 1.0 mg bid, everolimus 2 mg bid, or placebo. Patients received oral cyclosporine to achieve a target trough level of 150-400 ng/mL in combination with prednisone. Primary and secondary endpoints of safety, tolerability, and efficacy were determined at 12 months, and patients were followed through 36 months. There was a trend toward fewer treated acute rejections in the everolimus group than in the placebo group: everolimus 0.5 mg: 39.3%; everolimus 1.0 mg: 30.0%; everolimus 2 mg: 29.0%; placebo: 40.0% (P = not significant). Adverse events were higher in everolimus-treated patients especially at the 4-mg/day dose, but there was no difference in the incidence of thrombocytopenia or leukopenia between all groups and renal function as determined by serum creatinine, and creatinine clearance remained stable to 36 months in everolimus-treated patients. Mean cholesterol and triglycerides increased from baseline in all treatment groups, and maximum levels were seen at 6 months. In conclusion, this study demonstrates that everolimus in combination with oral cyclosporine had an acceptable safety and tolerability profile, paving the way for additional studies in this transplant indication.

AB - Everolimus is a macrolide immunosuppressive agent with known consistent absorption. In this double-blind study, we examined the safety and tolerability of everolimus vs. placebo in de novo liver transplant recipients. One hundred and nineteen liver allograft recipients were randomized to 1 of 4 groups: everolimus 0.5 mg bid, everolimus 1.0 mg bid, everolimus 2 mg bid, or placebo. Patients received oral cyclosporine to achieve a target trough level of 150-400 ng/mL in combination with prednisone. Primary and secondary endpoints of safety, tolerability, and efficacy were determined at 12 months, and patients were followed through 36 months. There was a trend toward fewer treated acute rejections in the everolimus group than in the placebo group: everolimus 0.5 mg: 39.3%; everolimus 1.0 mg: 30.0%; everolimus 2 mg: 29.0%; placebo: 40.0% (P = not significant). Adverse events were higher in everolimus-treated patients especially at the 4-mg/day dose, but there was no difference in the incidence of thrombocytopenia or leukopenia between all groups and renal function as determined by serum creatinine, and creatinine clearance remained stable to 36 months in everolimus-treated patients. Mean cholesterol and triglycerides increased from baseline in all treatment groups, and maximum levels were seen at 6 months. In conclusion, this study demonstrates that everolimus in combination with oral cyclosporine had an acceptable safety and tolerability profile, paving the way for additional studies in this transplant indication.

UR - http://www.scopus.com/inward/record.url?scp=33746058731&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=33746058731&partnerID=8YFLogxK

U2 - 10.1002/lt.20707

DO - 10.1002/lt.20707

M3 - Article

VL - 12

SP - 1640

EP - 1648

JO - Liver Transplantation

JF - Liver Transplantation

SN - 1527-6465

IS - 11

ER -